Treatment Strategies and Medications for APDS1

Treating APDS1 is a layered process that evolves with you or your child. Because the disease affects the immune system in two different ways—both making it weak and making it overactive—doctors use a combination of “shielding” the body from germs and “tuning” the immune system to stop it from overreacting.

Layer 1: Supportive Care (The Shield)

The first goal of treatment is to prevent the damage caused by frequent infections. Consider these supportive measures based on infection history, antibody function, and specialist assessment:

• Immunoglobulin Replacement Therapy (IgRT): This is a cornerstone of care. It provides you with healthy antibodies (IgG) from donors to help fight infections ^[1][2]. It is given intravenously (IVIG) or subcutaneously (SCIG). Discuss target levels and report any severe headaches.
• Prophylactic Antibiotics: Taking low doses of antibiotics daily can help prevent recurring sinus and lung infections, which is critical for preventing permanent lung damage like bronchiectasis ^[3]. Because antibiotics carry risks like resistance and C. difficile infection, they must be carefully prescribed and monitored.
• Vaccinations: While vaccine responses can be impaired, inactivated vaccines are often still recommended and may provide partial protection. Live-virus vaccines require individualized decisions based on immune function, IgRT use, and current drugs. Ask for a written vaccine plan ^[1].

Layer 2: Targeted Therapies (The Tuner)

These medications target the overactive PI3K-delta pathway. They do not correct the PIK3CD variant itself, and their use alongside IgRT depends on your phenotype and local approval.

Leniolisib (Joenja)

Approved in 2023 in certain jurisdictions (check your current local regulatory label), leniolisib is a highly specific “inhibitor” designed for APDS. It works like a precise brake on the “stuck” gas pedal of your immune cells ^[4].

• Efficacy: In clinical trials, it significantly reduced the size of swollen lymph nodes and spleens and helped normalize the levels of “naïve” B cells, which are essential for a healthy immune system ^[4][5]. This pathway control is encouraging, but improving cell counts does not establish prevention of all infections, bronchiectasis, or lymphoma.
• Age and Dosing: It is currently approved for adults and children aged 12 and older ^[5]. The standard dose is 70 mg taken orally twice daily ^[4]. Always refer to the current official label, as age, organ-function, and interaction-specific instructions vary.
• Safety & Monitoring: You must review every prescription, over-the-counter medicine, and supplement with your pharmacist to check for CYP3A-related interactions. The current label may require monitoring for blood counts, liver tests, or other laboratory abnormalities ^[4][6].

Sirolimus (Rapamycin)

Sirolimus is a broader medication used for many years before leniolisib was available. It blocks a protein called mTOR, which is downstream from the PI3K-delta protein ^[7].

• Efficacy: It is often very effective at shrinking swollen lymph nodes, though evidence for fixing bowel inflammation or low blood counts is variable and phenotype-specific ^[8][9].
• Safety: It requires careful blood level monitoring. Clinically important risks extend beyond kidney toxicity and mouth sores to include infection, cytopenias, lipid abnormalities, hypertension, and impaired wound healing ^[10][9].

Layer 3: Curative Care (The Reset)

Hematopoietic Stem Cell Transplantation (HSCT), often called a bone marrow transplant, can be potentially curative for the hematopoietic immune defect in carefully selected patients. It involves replacing the patient’s “overdrive” immune system with a healthy one from a donor, but it does not reverse established organ damage like bronchiectasis ^[11][3].

• When to Consider: It is usually reserved for patients with severe, life-threatening symptoms, or those who do not respond well to medications ^[11].
• Success Rates: In a retrospective cohort of 57 patients, the 2-year survival rate for APDS patients undergoing HSCT was approximately 86% ^[12]. Results vary widely by center and patient selection.
• Risks: The biggest challenge is graft failure (when the new cells don’t “take”), which occurs in about 17% of cases ^[12]. Other major risks include graft-versus-host disease, severe infection, and transplant-related mortality.
• The mTOR Factor: Research suggests that being on mTOR inhibitors (like sirolimus) during or shortly after the transplant may increase the risk of graft failure ^[12]. Discussing the timing of these medications with your transplant team is vital. Never stop sirolimus without transplant-team direction.

Treatment Decision Tree

This simplified guide shows how care is often approached based on age and severity:

Note: Always consult with an APDS specialist, as every case is unique. ^[13]

Practical Daily Management
Consider setting up a tracking system for daily medication adherence, managing IVIG versus subcutaneous IgRT schedules (including logging any infusion reactions), coordinating airway-clearance routines if you have bronchiectasis, and planning for travel or school absences. Always keep your team’s after-hours contact readily available.